Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yasuhiro Oki

Showing results (141-150 of 164) with videos related to

Pageof 17
Sort By:
British Journal of Haematology|June 26, 2013
Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphomaPhilippe Armand, Yasuhiro Oki, Donna S Neuberg, et al.
International Journal of Radiation Oncology, Biology, Physics|April 13, 2015
Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphomaChelsea C Pinnix, Grace L Smith, Sarah Milgrom, et al.
The Lancet. Oncology|December 8, 2015
Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trialMichael L Wang, Hun Lee, Hubert Chuang, et al.
British Journal of Haematology|September 12, 2015
CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphomaKoichi Takahashi, Mariela Sivina, Julia Hoellenriegel, et al.
Scientific Reports|February 6, 2019
A PET Radiomics Model to Predict Refractory Mediastinal Hodgkin LymphomaSarah A Milgrom, Hesham Elhalawani, Joonsang Lee, et al.
Cancer|May 4, 2018
Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphomaJorge E Romaguera, Michael Wang, Lei Feng, et al.
International Journal of Radiation Oncology, Biology, Physics|February 18, 2018
Radiation Therapy as an Effective Salvage Strategy for Secondary CNS LymphomaSarah A Milgrom, Chelsea C Pinnix, T Linda Chi, et al.
The Lancet. Oncology|December 3, 2014
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trialNathan H Fowler, R Eric Davis, Seema Rawal, et al.
British Journal of Haematology|December 17, 2016
The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphomaDai Chihara, Michelle A Fanale, Roberto N Miranda, et al.
Blood Advances|November 14, 2022
A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCLHua-Jay J Cherng, Stefan K Alig, Yasuhiro Oki, et al.
Pageof 17

Showing results (141-150 of 164) with videos related to

Sort By:
Pageof 17
British Journal of Haematology|June 26, 2013
Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphomaPhilippe Armand, Yasuhiro Oki, Donna S Neuberg, et al.
International Journal of Radiation Oncology, Biology, Physics|April 13, 2015
Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphomaChelsea C Pinnix, Grace L Smith, Sarah Milgrom, et al.
The Lancet. Oncology|December 8, 2015
Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trialMichael L Wang, Hun Lee, Hubert Chuang, et al.
British Journal of Haematology|September 12, 2015
CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphomaKoichi Takahashi, Mariela Sivina, Julia Hoellenriegel, et al.
Scientific Reports|February 6, 2019
A PET Radiomics Model to Predict Refractory Mediastinal Hodgkin LymphomaSarah A Milgrom, Hesham Elhalawani, Joonsang Lee, et al.
Cancer|May 4, 2018
Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphomaJorge E Romaguera, Michael Wang, Lei Feng, et al.
International Journal of Radiation Oncology, Biology, Physics|February 18, 2018
Radiation Therapy as an Effective Salvage Strategy for Secondary CNS LymphomaSarah A Milgrom, Chelsea C Pinnix, T Linda Chi, et al.
The Lancet. Oncology|December 3, 2014
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trialNathan H Fowler, R Eric Davis, Seema Rawal, et al.
British Journal of Haematology|December 17, 2016
The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphomaDai Chihara, Michelle A Fanale, Roberto N Miranda, et al.
Blood Advances|November 14, 2022
A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCLHua-Jay J Cherng, Stefan K Alig, Yasuhiro Oki, et al.
Pageof 17